MX2016006743A - Ensayo de puente a base de resonancia de plasmon superficial para determinar la actividad biologica de moleculas multiespecificas multivalentes. - Google Patents

Ensayo de puente a base de resonancia de plasmon superficial para determinar la actividad biologica de moleculas multiespecificas multivalentes.

Info

Publication number
MX2016006743A
MX2016006743A MX2016006743A MX2016006743A MX2016006743A MX 2016006743 A MX2016006743 A MX 2016006743A MX 2016006743 A MX2016006743 A MX 2016006743A MX 2016006743 A MX2016006743 A MX 2016006743A MX 2016006743 A MX2016006743 A MX 2016006743A
Authority
MX
Mexico
Prior art keywords
biological activity
spr
multivalent
determining
multispecific molecules
Prior art date
Application number
MX2016006743A
Other languages
English (en)
Inventor
Moelleken Joerg
Kettenberger Hubert
Thomas Regula Joerg
Papadimitriou Apollon
Gassner Christian
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2016006743A publication Critical patent/MX2016006743A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/55—Specular reflectivity
    • G01N21/552—Attenuated total reflection
    • G01N21/553—Attenuated total reflection and using surface plasmons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/65—Raman scattering
    • G01N21/658—Raman scattering enhancement Raman, e.g. surface plasmons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)

Abstract

En este documento se describe el uso de un ensayo de unión de un anticuerpo biespecífico bivalente que tiene el valor kD (constante de disociación) más pequeño para la interacción con su antígeno para la inmovilización del anticuerpo biespecífico bivalente a una superficie sólida para la determinación de la actividad biológica del anticuerpo biespecífico bivalente.
MX2016006743A 2013-12-13 2014-12-09 Ensayo de puente a base de resonancia de plasmon superficial para determinar la actividad biologica de moleculas multiespecificas multivalentes. MX2016006743A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13197264 2013-12-13
PCT/EP2014/076953 WO2015086549A1 (en) 2013-12-13 2014-12-09 Spr-based bridging assay for determining the biological activity of multivalent, multispecific molecules

Publications (1)

Publication Number Publication Date
MX2016006743A true MX2016006743A (es) 2016-08-12

Family

ID=49765899

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016006743A MX2016006743A (es) 2013-12-13 2014-12-09 Ensayo de puente a base de resonancia de plasmon superficial para determinar la actividad biologica de moleculas multiespecificas multivalentes.

Country Status (8)

Country Link
US (3) US20170003295A1 (es)
EP (1) EP3080606B1 (es)
JP (1) JP6568521B2 (es)
KR (1) KR20160098239A (es)
CN (1) CN105829889B (es)
CA (1) CA2928101A1 (es)
MX (1) MX2016006743A (es)
WO (1) WO2015086549A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11867696B2 (en) 2015-02-06 2024-01-09 Cell Idx, Inc. Antigen-coupled immunoreagents
WO2017097918A1 (en) * 2015-12-09 2017-06-15 F. Hoffmann-La Roche Ag Method for determining the in vivo interaction mode
US12123874B2 (en) * 2016-07-18 2024-10-22 Cell Idx, Inc. Reagent compounds, compositions, kits, and methods for amplified assays
EP3519820B1 (en) * 2016-09-30 2020-12-09 H. Hoffnabb-La Roche Ag Spr-based dual-binding assay for the functional analysis of multispecific molecules
WO2019200326A1 (en) 2018-04-13 2019-10-17 Rarecyte, Inc. Kits for labeling of biomarkers and methods of using the same
WO2019235420A1 (ja) * 2018-06-04 2019-12-12 中外製薬株式会社 複合体を検出する方法
CN119716045A (zh) * 2018-12-30 2025-03-28 豪夫迈·罗氏有限公司 基于pH梯度SPR的结合测定
WO2020200941A1 (en) * 2019-03-29 2020-10-08 F. Hoffmann-La Roche Ag Spr-based binding assay for the functional analysis of multivalent molecules
CN114088947B (zh) * 2021-11-08 2023-10-13 上海药明生物医药有限公司 一种利用混合抗体捕获法筛选VHH/scFv的方法
EP4437344A1 (en) * 2021-11-25 2024-10-02 F. Hoffmann-La Roche AG Quantification of low amounts of antibody sideproducts

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
TWI426920B (zh) * 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
EP2872534B1 (en) * 2012-07-13 2018-08-08 Roche Glycart AG Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases

Also Published As

Publication number Publication date
CN105829889B (zh) 2019-03-08
JP2016540212A (ja) 2016-12-22
EP3080606B1 (en) 2019-08-28
US20240077495A1 (en) 2024-03-07
KR20160098239A (ko) 2016-08-18
WO2015086549A1 (en) 2015-06-18
US20170003295A1 (en) 2017-01-05
JP6568521B2 (ja) 2019-08-28
EP3080606A1 (en) 2016-10-19
CA2928101A1 (en) 2015-06-18
US20210199666A1 (en) 2021-07-01
CN105829889A (zh) 2016-08-03

Similar Documents

Publication Publication Date Title
MX2016006743A (es) Ensayo de puente a base de resonancia de plasmon superficial para determinar la actividad biologica de moleculas multiespecificas multivalentes.
EA201300978A1 (ru) Антитела к сеа
EA201591806A1 (ru) Лечение и профилактика острой почечной недостаточности с применением анти-альфа-v-бета-5 антител
EA201492101A1 (ru) Антитела против fcrn
MX359794B (es) Anticuerpos anti-hepcidina y usos de los mismos.
MX2017001401A (es) Constructos de anticuerpos de cadena sencilla biespecifica especificos para especies cruzadas optimizadas.
AR094403A1 (es) Terapia de combinación de anticuerpos anti-her3
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
NZ628314A (en) Cd47 antibodies and methods of use thereof
EA201592269A1 (ru) Способы и композиции для снижения иммуносупрессии опухолевыми клетками
BR112014012590A8 (pt) Anticorpos anti-cd98 e métodos de uso dos mesmos
NZ717673A (en) Anti-alpha-synuclein antibodies and methods of use
EA201200998A1 (ru) Способы лечения рака поджелудочной железы
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
BR112016019866A2 (pt) terapias de combinação com anticorpos anti-cd38
EA201600354A1 (ru) Антигенсвязывающая молекула, содержащая вариабельную область антитела
TN2013000417A1 (en) Antibody polypeptides that antagonize cd40
EA201400579A1 (ru) Антитела к il-36r
MX2015010427A (es) Anticuerpos anti-tnf-alfa altamente galactosilados y sus usos.
EA201600474A1 (ru) Комбинированная терапия с использованием антитела к ang2 и агониста cd40
EA201201016A1 (ru) Антидоты антикоагулянтов
EA201690992A1 (ru) Антитела, специфичные к fcrn
MX2015003541A (es) Metodos para identificar los anticuerpos con inmunogenia reducida.
CL2011000931A1 (es) Anticuerpo humanizado anti-alfa2 integrina; uso del anticuerpo antes mencionado para tratar cancer.
GB201202223D0 (en) Immunoassay for pyrrolidinophenones